Cancer immunotherapy via dendritic cells
Nature Reviews Cancer, ISSN: 1474-175X, Vol: 12, Issue: 4, Page: 265-277
2012
- 1,688Citations
- 1,933Captures
- 4Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1,688
- Citation Indexes1,680
- 1,680
- CrossRef1,456
- Patent Family Citations7
- Patent Families7
- Policy Citations1
- Policy Citation1
- Captures1,933
- Readers1,933
- 1,933
- Mentions4
- News Mentions2
- News2
- References2
- Wikipedia2
Most Recent News
DENV Peptides Delivered as Spherical Nucleic Acid Constructs Enhance Antigen Presentation and Immunogenicity in vitro and in vivo
Introduction Dengue virus (DENV), a member of the flavivirus genus within the Flaviviridae family, is a single-stranded, positive-sense RNA virus primarily transmitted by Aedes aegypti
Review Description
Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy. In one approach, autologous antigen-specific T cells are expanded ex vivo and then re-infused into patients. Another approach is through vaccination; that is, the provision of an antigen together with an adjuvant to elicit therapeutic T cells in vivo. Owing to their properties, dendritic cells (DCs) are often called 'nature's adjuvants' and thus have become the natural agents for antigen delivery. After four decades of research, it is now clear that DCs are at the centre of the immune system owing to their ability to control both immune tolerance and immunity. Thus, DCs are an essential target in efforts to generate therapeutic immunity against cancer. © 2012 Macmillan Publishers Limited. All rights reserved.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84858780815&origin=inward; http://dx.doi.org/10.1038/nrc3258; http://www.ncbi.nlm.nih.gov/pubmed/22437871; https://www.nature.com/articles/nrc3258; https://dx.doi.org/10.1038/nrc3258; http://www.nature.com/nrc/journal/v12/n4/full/nrc3258.html; http://www.nature.com/doifinder/10.1038/nrc3258
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know